Dan Jing Chang is the Chief Operating Officer, bringing over a decade of experience in clinical innovation, digital health, and biomedical product strategy. With a background spanning emergency medicine, regulatory compliance (IRB, GCP, ISO 13485/14971), and digital transformation, she bridges the gap between research and real-world application.​

Ms. Chang has led multi-center first-in-human trials, established a national biomedical data repository, and secured over USD 1 million in startup funding. She also directed government-backed AI health projects totaling more than TWD 50 million. Her expertise in product positioning, cross-disciplinary collaboration, and regulatory navigation has accelerated the company’s transition from R&D to market.​

Currently, she focuses on building data-driven regenerative medicine solutions—applying machine learning to organoid quality control and driving productization in the preclinical NAMs (New Approach Methodologies) space. With a long-term vision centered on longevity and scalable clinical application, Ms. Chang plays a key role in delivering innovative, regulatory-ready platforms for the future of organoid-based healthcare.